GoAI
Get started
Acumen Pharmaceuticals, Inc. logo

Acumen Pharmaceuticals, Inc.

ABOS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.16

−$0.03 · -0.94%

Aug 21, 4:00 PM ET

ABOS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

30

Expensive

Momentum

57

Neutral

Sentiment

55

Mixed

Risk resilience

49

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Daniel J. O'Connell
Listed since
Jul 1, 2021
Employees
61

Market position

Day range

Current $3.16

52-week range

Current $3.16

Open
$3.215
Previous close
$3.19
Volume
716.03K
1.68× average
Average volume
427.11K
Average daily volume
Market cap
228.24M USD
Beta
0.33
Market reference 1
50-day average
$2.4444
+29.28% above average
200-day average
$2.3854
+32.47% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-1.93×
P/B (TTM)
3.99×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0.55×

Financial statements

Income trends

Operating income

−123.83M USD-8.61%

Net income

−121.34M USD-18.57%
Income trends across reported periods−9.16M USD−50.86M USD−92.56M USD−134.26M USDOperating income, FY2021: −19.58M USDOperating income, FY2022: −45.24M USDOperating income, FY2023: −61.14M USDOperating income, FY2024: −114.02M USDOperating income, FY2025: −123.83M USDNet income, FY2021: −100.61M USDNet income, FY2022: −42.86M USDNet income, FY2023: −52.37M USDNet income, FY2024: −102.33M USDNet income, FY2025: −121.34M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −19.58M USD. Operating income FY2022 −45.24M USD. Operating income FY2023 −61.14M USD. Operating income FY2024 −114.02M USD. Operating income FY2025 −123.83M USD. Net income FY2021 −100.61M USD. Net income FY2022 −42.86M USD. Net income FY2023 −52.37M USD. Net income FY2024 −102.33M USD. Net income FY2025 −121.34M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold————12.31M USD
Gross profit————−12.31M USD
Research and development104.89M USD93.8M USD42.32M USD32.36M USD12.31M USD
Selling, general, and administrative18.95M USD20.22M USD18.82M USD12.88M USD7.28M USD
Operating expenses123.83M USD114.02M USD61.14M USD45.24M USD7.28M USD
Interest income7.45M USD14.32M USD10.79M USD2.39M USD84K USD
Interest expense4.22M USD4.07M USD581K USD——
Depreciation and amortization184K USD178K USD184K USD169K USD4K USD
Operating income−123.83M USD−114.02M USD−61.14M USD−45.24M USD−19.58M USD
Net income−121.34M USD−102.33M USD−52.37M USD−42.86M USD−100.61M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

7 ratings
Strong buy00%
Buy7100%
Hold00%
Sell00%
Strong sell00%

ABOS news

seekingalpha.com

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Acumen Pharmaceuticals Q2 Earnings Call Highlights

Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target…

Read source
globenewswire.com

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble…

Read source
globenewswire.com

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble…

Read source
zacks.com

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.

Read source
zacks.com

All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy

Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read source

ABOS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research ABOS

research.disclaimer